Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024
Portfolio Pulse from
Viking Therapeutics announced positive results from its Phase 2b VOYAGE study of VK2809 for NASH/MASH, achieving primary and secondary endpoints with promising safety and tolerability.
November 19, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Viking Therapeutics' VK2809 achieved primary and secondary endpoints in a Phase 2b study for NASH/MASH, showing robust liver fat reductions and promising safety, potentially enhancing its market position.
The successful achievement of primary and secondary endpoints in the Phase 2b study of VK2809, along with its promising safety profile, suggests a strong potential for the drug in treating NASH/MASH. This could lead to increased investor confidence and a positive impact on Viking Therapeutics' stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100